04:43:18 EST Fri 28 Jan 2022
Enter Symbol
or Name

Cannabis Summary for Jan. 12, 2022

2022-01-12 20:12 ET - Market Summary

This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.

Here is a sample of this item:

by Stockwatch Business Reporter

The S&P/TSX Cannabis Index lost 2.47 to 91.40, while the CSE Composite Index added a fraction to 517.93. On a slow news day, the big news in cannabis circles was a popular science article published late yesterday by Forbes. "Study Finds Cannabis Compounds Prevent Infection by COVID-19 Virus," proclaimed the headline. The story soon made its way into dozens of other media outlets, from Bloomberg to the New York Post.

The article discussed a study published this week by researchers affiliated with Oregon State University. They found that two cannabinoids, CBGA and CBDA, can prevent the virus that causes COVID-19 from entering cells. "Orally bioavailable and with a long history of safe human use, these cannabinoids, isolated or in hemp extracts, have the potential to prevent as well as treat infection by SARS-CoV-2," wrote the researchers in their study (published this week in the Journal of Natural Products).

The key word is potential. This was an in vitro study, meaning it was done in petri dishes rather than human bodies (or even mice bodies). Whether the doses used in the study are feasible for consumption, and by what method -- presumably not the most common method of smoking, as compounds can break down when exposed to heat -- was not the point. At best, this is an interesting preliminary finding. (Similarly, the veterinary drug ivermectin had early studies suggesting a benefit against COVID, but subsequent trials turned up no high-quality evidence that it is actually effective.) Certainly there are plenty of regular cannabis users who have caught the virus.

The remainder is available to Stockwatch subscribers.
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

© 2022 Canjex Publishing Ltd. All rights reserved.

Reader Comments - Comments are open to paying subscribers of Stockwatch and unmoderated, although libelous remarks, obscene language and impersonations may be deleted. Opinions expressed do not necessarily reflect the views of Stockwatch.
For information regarding Canadian libel law, please view the University of Ottawa's FAQ regarding Defamation and SLAPPs.